Leadership from the Innovation & Value Initiative, along with experts in mental health and a representative from employer purchasing group, discuss strategies for creating value-based decisions in mental health coverage.
In the latest Matters in Managed Care webinar, experts discussed the current state of mental health care, including the growing consensus on the need for change, strategies to provide high value care, and opportunities for collaboration among payers and other healthcare stakeholders.
The speakers highlighted common challenges for employers and payers regarding coverage for mental health care; discussed common definitions of value for payers, employers, and people with lived experience; shared strategies to incentivize high-value interventions for mental health care; and identified opportunities for future collaboration.
The speakers were:
In segment 4, they discussed IVI's open source project in mental health.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Managed Care Reflections: A Q&A With John Michael O’Brien, PharmD, MPH
May 5th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The May issue features a conversation with John Michael O’Brien, PharmD, MPH, a member of AJMC’s editorial board and the president and CEO of the National Pharmaceutical Council. This interview has been lightly edited for clarity.
Read More